-

Musa Tariq Joins Guardant Health Board of Directors

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.

“We are very pleased to welcome Musa Tariq to our board of directors,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Musa brings a wealth of knowledge and expertise in building some of the world’s most recognized brands. His insights will be extremely valuable as we continue to build our brand and shape the company’s next chapter to empower every individual to stay one step ahead of cancer.”

Since joining GoFundMe in January 2021, Tariq has been recognized for his leadership in Forbes’ Entrepreneurial CMO List 2022, and in Insider’s Most Innovative CMOs of 2022. Before his role with GoFundMe, Tariq was global head of marketing for Airbnb Experiences where he drove brand awareness and adoption of that rapidly growing part of Airbnb’s business. Prior to Airbnb, he was chief brand officer at Ford Motor Company and also held marketing leadership roles at Apple, Nike and Burberry.

“I am excited to join the Guardant Health board at such a pivotal time in the company’s evolution,” said Tariq. “Guardant is a leader in helping patients at all stages of cancer live longer and healthier lives, and now they’ve developed a simple blood test to find cancer early, when it’s most treatable. I look forward to working with the company’s leadership team to advance its mission to transform the future of cancer care.”

A distinguished counselor to iconic and emerging global brands, Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other starts ups. He has a B.S. in Geography and Economics from London School of Economics.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

More News From Guardant Health, Inc.

UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl...

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha...

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese...
Back to Newsroom